| |
Malignancy n(%) |
Death n(%) |
| |
Yes |
No |
Yes |
No |
| DM |
6 (8.1) |
68 (91.9) |
7 (9.5%) |
67(90.5%) |
| PM |
3 (15) |
17 (85) |
1(5) |
19 (95) |
| OS |
2 (8.3) |
22 (91.7) |
4 (16.7) |
20 (83.3) |
Female
Male |
9 (10.8)
2 (5.7) |
74 (89.2)
33 (94.3) |
7 (8.4)
5 (14.3) |
76 (91.6)
30 (85.7%) |
| High CPK |
11 (11.2) |
87 (88.8) |
9 (9.2) |
89 (90.8) |
| Cutaneous signs |
7 (8.1) |
79 (91.9) |
9 (10.5) |
77 (89.5) |
| Raynaud phenomenon |
0 |
23 (100) |
3 (13) |
20 (87) |
| Low Hb |
4 (9.1) |
40 (90.9) |
3 (6.8) |
41 (93.2) |
| High Cr |
0 |
1 (100) |
0 |
1 (100%) |
| Low Alb |
4 (8) |
46 (92) |
7 (14) |
43 (86) |
| High LDH |
11 (10.9) |
90 (89.1) |
10 (9.9) |
91 (90.1) |
| High ESR |
3 (7.1) |
39 (92.9) |
4 (9.5) |
38 (90.5) |
| Corticosteroid use |
11 (9.4) |
104 (90.4) |
10 (8.7) |
105 (91.3) |
| Cytotoxic drugs use |
6 (6.2) |
91 (93.8) |
5 (5.2) |
92 (94.8) |
| Chloroquine use |
2 (6.9) |
29 (93.5) |
1 (3.2) |
30 (96.8) |
|
